OncoMatch/Clinical Trials/NCT06760039

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

Is NCT06760039 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including R-CMOP Regimen and R-CHOP Regimen for diffuse large b-cell lymphoma.

Phase 1/2RecruitingSun Yat-sen UniversityNCT06760039Data as of May 2026

Treatment: R-CMOP Regimen · R-CHOP Regimen — This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: antitumor therapy

Lab requirements

Blood counts

sufficient bone marrow function

Kidney function

sufficient kidney function

Liver function

sufficient liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify